Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 44, 2013, Pages 17832-17837

  Reshetnyak, Andrey V ^a   Nelson, Bryce ^b   Shi, Xiarong ^a   Boggon, Titus J ^a   Pavlenco, Alevtina ^b   Mandel Bausch, Elizabeth M ^c   Tome, Francisco ^a   Suzuki, Yoshihisa ^c   Sidhu, Sachdev S ^b   Lax, Irit ^a   Schlessinger, Joseph ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Kolltan Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KIT ANTIBODY; KIT RECEPTOR TYROSINE KINASE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN STRUCTURE;

CANCER THERAPY; CELL SIGNALING; PHOSPHORYLATION; PROTEIN KINASE; THERAPEUTIC ANTIBODIES;

ANIMALS; ANTIBODIES, MONOCLONAL; BACULOVIRIDAE; CELL SURFACE DISPLAY TECHNIQUES; CRYSTALLIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-KIT; SF9 CELLS; SPODOPTERA;

EID: 84887100172     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1317118110     Document Type: Article

References (27)

1. Zhang Z, Zhang R, Joachimiak A, Schlessinger J, Kong XP (2000) Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA 97(14):7732-7737.
2. Jiang X, et al. (2000) Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J 19(13):3192-3203.
3. Fleischman RA (1993) From white spots to stem cells: The role of the Kit receptor in mammalian development. Trends Genet 9(8):285-290.
4. Huizinga JD, et al. (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512):347-349.
5. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117-1134.
6. Roskoski R, Jr. (2005) Signaling by Kit protein-Tyrosine kinase-The stem cell factor receptor. Biochem Biophys Res Commun 337(1):1-13.
7. Yuzawa S, et al. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130(2):323-334.
8. Mol CD, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c- Kit tyrosine kinase. J Biol Chem 279(30):31655-31663.
9. Mol CD, et al. (2003) Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278(34):31461-31464.
10. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211-225.
11. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J (1997) Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272(10):6311-6317.
12. Liu H, Chen X, Focia PJ, He X (2007) Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J 26(3):891-901.
13. Ashman LK, Griffith R (2013) Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 22(1):103-115.
14. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer 11(12):865-878.
15. Gajiwala KS, et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106(5):1542-1547.
16. Swain SM, et al. (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461-471.
17. Baselga J, et al.; CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119.
18. Persson H, et al. (2013) CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol 425(4):803-811.
19. Nelson B, Sidhu SS (2012) Synthetic antibody libraries. Methods Mol Biol 899:27-41.
20. Guo T, et al. (2007) Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13(16):4874-4881.
21. Yang Y, Xie P, Opatowsky Y, Schlessinger J (2010) Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc Natl Acad Sci USA 107(5):1906-1911.
22. Yang Y, Yuzawa S, Schlessinger J (2008) Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci USA 105(22):7681-7686.
23. Arkhipov A, et al. (2013) Architecture and membrane interactions of the EGF receptor. Cell 152(3):557-569.
24. Endres NF, et al. (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152(3):543-556.
25. Blechman JM, et al. (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80(1):103-113.
26. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(pt 4): 658-674.
27. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67(pt 4):235-242.